Genmab raises guidance ahead of annual report

Sales of the Genmab-developed cancer drug Darzalex have been so strong throughout 2016 that the biotech is raising its financial guidance for 2016 just a few weeks before the publication of the annual report.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Get 14 days free trial access

Frontpage right now

Latest Top picks in English

Related articles